850689-27-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 3-Amino-5-boronobenzoate, pinacol ester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be readily incorporated into complex molecular structures. Its reactivity in cross-coupling reactions facilitates the creation of diverse medicinal compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 3-Amino-5-boronobenzoate, pinacol ester is utilized as a versatile building block for the assembly of organic compounds. Its boronic acid derivative nature allows it to participate in various coupling reactions, contributing to the formation of a wide array of organic molecules with different functionalities.
Used in Drug Discovery and Development:
Methyl 3-Amino-5-boronobenzoate, pinacol ester is employed in drug discovery and development processes due to its potential to exhibit biological activity. Its unique structure may contribute to the design of new drugs with specific target interactions, making it a promising candidate for further research and development in medicinal chemistry.
Used in Chemical Research:
As a valuable tool in chemical research, Methyl 3-Amino-5-boronobenzoate, pinacol ester is used to explore new reaction pathways and mechanisms. Its participation in Suzuki-Miyaura cross-coupling reactions provides insights into the synthesis of complex organic molecules, advancing the understanding of chemical bond formation and the development of novel synthetic methods.

Upstream product

• 42237-85-4 3-amino-5-bromobenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 706791-83-5 3-amino-5-bromobenzoic acid methyl ester 
• 380430-56-8 (3-amino-5-(methoxycarbonyl)phenyl)boronic acid 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 651014-90-3 C₁₈H₂₆BNO₅ 
• 1009093-74-6 C₄₇H₆₅N₅O₇ 
• 1009093-76-8 C₃₆H₄₉N₃O₈ 
• 1009093-75-7 C₁₇H₂₄BNO₅ 

Relevant academic research and scientific papers

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Exploration of Alternative Scaffolds for P2Y14Receptor Antagonists Containing a Biaryl Core

Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y14 receptor (P2Y14R) antagonists were synthesized, and affinity was measured in P2Y14R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y14R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 ≈ 20 nM at hP2Y14R/mP2Y14R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y14R antagonist structure-activity relationship, introducing diverse physical-chemical properties.

HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS

Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are

Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.